- $238.29bn
- $264.84bn
- $45.81bn
- 93
- 26
- 70
- 66
REG - AstraZeneca PLC - Truqap approved in US for HR+ breast cancer
AnnouncementREG - AstraZeneca PLC - Update on PACIFIC-2 Phase III trial for Imfinzi
AnnouncementREG - AstraZeneca PLC - Director Declaration
AnnouncementREG - AstraZeneca PLC - 9M and Q3 2023 results
AnnouncementREG - AstraZeneca PLC - Agreement with Eccogene for clinical stage GLP-1RA
AnnouncementREG - AstraZeneca PLC - Imfinzi combination improves PFS in liver cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca cell & gene therapy deal w/ Cellectis
AnnouncementREG - Stock Exch Notice - Admission to Trading - 30/10/2023
AnnouncementREG - Official List - Amendment Notice
AnnouncementRCS - SYSTRAN - SYSTRAN Translate Server Version 10 Unveiled
AnnouncementREG - AstraZeneca PLC - AstraZeneca settles Nexium liability litigations
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd improved PFS in breast cancer
AnnouncementREG - AstraZeneca PLC - Alexion completes Pfizer gene therapy agreement
AnnouncementREG - AstraZeneca PLC - Enhertu recommended in EU for HER2-mutant NSCLC
AnnouncementREG - AstraZeneca PLC - Fasenra Phase III EGPA trial met primary endpoint
AnnouncementREG - AstraZeneca PLC - Update on US review of Ultomiris for NMOSD
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
Announcement